Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ABPI And Top Pharma Execs Come Out Against Brexit

Executive Summary

The Association of the British Pharmaceutical Industry has formally come out in support of the UK remaining part of the EU, saying that a vote to leave in next month's referendum would lead to delays in the availability of new drugs, have a detrimental effect on collaboration in European drug research, and discourage inward investment by international drug firms.

You may also be interested in...



Brexit Corporate Stock-Taking: Keep Calm And Carry On

Although the overwhelming voice of the pharma industry had been in favor of the UK remaining in the EU, business reaction to the Leave result was muted, and the general message was that there would be no noticeable impact on individual companies, at least for the time being.

UK On A Knife Edge As EU Referendum Nears

With the UK about to go to the polls in a once-and-for-all decision on EU membership, the stakes for the life sciences sector are high. The effects of a Brexit would be far-reaching, not only for the industry but also for other key groups such as regulators, patients and researchers.

Brexit Would Hit UK Life Sciences Hard, Says Parliamentary Committee

UK parliamentary committee warns that a vote to leave the EU would have negative effects on life science companies, such as impairing cross-border business and research collaboration, and calls on the government to prepare contingency measures should the June 23 referendum result in a Brexit.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC065136

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel